Ablynx aims to launch llama-based arthritis drug in 2013

01/26/2010 | Reuters

Ablynx CEO Edwin Moses said the Belgian company expects to launch its first llama-derived nanomedicine as early as 2013 through a partnership with Pfizer. The drug, which was developed from extra-small antibodies from llamas, could replace Pfizer's Enbrel as a blockbuster treatment for rheumatoid arthritis.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY